USFDA warning letter for Glenmark's Baddi unit, reason classified

The company believes that the existing manufacturing and the sale of products from this facility will not be impacted, it added.

Drug firm Glenmark Pharmaceuticals on Saturday said it has received a warning letter from the US health regulator for its Baddi facility in Himachal Pradesh.

The United States Food and Drug Administration (USFDA) had inspected the facility between April 15 and April 20 and earlier classified the inspection as an official action indicated, Glenmark said in a filing to the BSE.

The warning letter issued is regarding the same inspection, it added. "The company is committed to work along with the USFDA to implement all the necessary corrective actions required to address the concerns raised in the letter and is in the process of preparing a detailed response to the USFDA within 15 working days," Glenmark said.

The company believes that the existing manufacturing and the sale of products from this facility will not be impacted, it added.

The Baddi facility is expected to contribute $30 million in total sales for this financial year which is about 7 per cent of the total US sales, Glenmark said. "There are no major pending approvals from this facility in the next 12 months. There will be no financial impact on the organisation on account of this development," it added.

Currently, the company has eight manufacturing facilities approved by the USFDA — five formulations' facilities and three API facilities under Glenmark Life Sciences Ltd. None of these facilities except Baddi has any outstanding issues with the USFDA at this point in time, Glenmark said.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel